New Doses of Mounjaro Arrive in Brazil with Prices Ranging from R$ 2.6k to R$ 3.6k
The new 7.5 mg and 10 mg doses of the Mounjaro (tirzepatide) medication will arrive in Brazilian pharmacies in September 2025 to treat type 2 diabetes and obesity, with a monthly cost between R$ 2.6k and R$ 3.6k.
New Doses of Mounjaro Arrive in Brazil with Defined Prices
Starting in September 2025, new 7.5 mg and 10 mg doses of Mounjaro (tirzepatide), a medication for the treatment of type 2 diabetes and obesity, will be available in Brazilian pharmacies. The monthly treatment, which includes four applicator pens, will cost between R$ 2.6k and R$ 3.6k, depending on the dosage and sales channel.
Drug Release and Gradual History
Mounjaro, produced by pharmaceutical company Eli Lilly, was approved by Anvisa in September 2023 for type 2 diabetes and, subsequently, in June 2025, for overweight and obesity. The gradual introduction of doses, starting with 2.5 mg and 5 mg concentrations, is a common strategy to reduce gastrointestinal side effects, with the 7.5 mg and 10 mg doses serving as intermediaries for greater efficacy.
Mechanism of Action and Impact on the Brazilian Market
Tirzepatide acts by activating GIP and GLP-1 receptors, hormones of the digestive system, which promote insulin release and control appetite, aiding in glycemic management and weight loss. The arrival of these new doses is significant for Brazil, where over 10% of the adult population has diabetes and 57% are overweight, making it a relevant market for therapies like this.
{"title":"New Doses of Mounjaro Arrive in Brazil with Prices Ranging from R$ 2.6k to R$ 3.6k","desc":"The new 7.5 mg and 10 mg doses of the Mounjaro (tirzepatide) medication will arrive in Brazilian pharmacies in September 2025 to treat type 2 diabetes and obesity, with a monthly cost between R$ 2.6k and R$ 3.6k.","author":"G1","tags":"Health","sourceUrl":"https://g1.globo.com/saude/noticia/2025/09/15/novas-doses-de-mounjaro-chegam-ao-brasil-com-precos-entre-r-26-mil-e-r-36-mil.ghtml","topImage":"https://v17-def.ap4r.com/kos/s101/nlav11312/ug-ai-seo-imgs/7bff884e-2bde-405d-a04e-e5ce0924e370.jpg","paragraphList":[{"paraTitle":"New Doses of Mounjaro Arrive in Brazil with Defined Prices","paraContent":"Starting in September 2025, new 7.5 mg and 10 mg doses of Mounjaro (tirzepatide), a medication for the treatment of type 2 diabetes and obesity, will be available in Brazilian pharmacies. The monthly treatment, which includes four applicator pens, will cost between R$ 2.6k and R$ 3.6k, depending on the dosage and sales channel."},{"paraTitle":"Drug Release and Gradual History","paraContent":"Mounjaro, produced by pharmaceutical company Eli Lilly, was approved by Anvisa in September 2023 for type 2 diabetes and, subsequently, in June 2025, for overweight and obesity. The gradual introduction of doses, starting with 2.5 mg and 5 mg concentrations, is a common strategy to reduce gastrointestinal side effects, with the 7.5 mg and 10 mg doses serving as intermediaries for greater efficacy."},{"paraTitle":"Mechanism of Action and Impact on the Brazilian Market","paraContent":"Tirzepatide acts by activating GIP and GLP-1 receptors, hormones of the digestive system, which promote insulin release and control appetite, aiding in glycemic management and weight loss. The arrival of these new doses is significant for Brazil, where over 10% of the adult population has diabetes and 57% are overweight, making it a relevant market for therapies like this."}],"metaInfo":{"keywords":"Brazil, health, international","sitename":"G1","description":"New doses of Mounjaro (7.5 mg and 10 mg) arrive in Brazil in September 2025 to treat diabetes and obesity, with monthly prices between R$ 2.6k and R$ 3.6k.","language":"en"},"pubDate":"2025-09-16","traceId":"ecf2084a-b4cc-4273-9efe-b4e9aec44d14"}